2007 JASN IMPACT FACTOR 7.111	HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP
advanced	CURRENT ISSUE	ARCHIVES	JASN Express	ONLINE SUBMISSION

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hsu, C.-y. Articles by Curhan, G. C. Search for Related Content PubMed PubMed Citation Articles by Hsu, C.-y. Articles by Curhan, G. C.

Epidemiology of Anemia Associated with Chronic Renal Insufficiency among Adults in the United States: Results from the Third National Health and Nutrition Examination Survey

Chi-yuan Hsu^*, Charles E. McCulloch and Gary C. Curhan

*Division of Nephrology, Division of Biostatistics, University of California, San Francisco, San Francisco, California; and Channing Laboratory, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts.

Correspondence to: Dr. Chi-yuan Hsu, Division of Nephrology, University of California, San Francisco, Room 672 HSE, Box 0532, 513 Parnassus Avenue, San Francisco, CA 94143-0532. Phone: 415-353-2379; Fax: 415-476-3381; E-mail: hsuchi{at}medicine.ucsf.edu

	Abstract

Top Abstract Introduction Materials and Methods Results Discussion References

 
ABSTRACT. Anemia associated with chronic renal insufficiency (CRI) may have substantial clinical and public health importance, but little is known about its epidemiology. This study aims to quantify the relationship between reduced renal function and hemoglobin level, to assess the iron status of subjects with CRI, and to estimate the burden of anemia associated with CRI. The Third National Health and Nutrition Examination Survey (NHANES III) (1988 to 1994) data on 15,971 adults aged >18 yr with measurements of serum creatinine, hemoglobin, and iron profile were analyzed. General linear models were used to determine the relationship between hemoglobin level and Cockcroft-Gault creatinine clearance (CrCl) and to estimate the likelihood of anemia at different levels of renal function in different demographic subgroups. Sample weights were used to produce weighted regression parameters and population estimates. A statistically significant decrease in hemoglobin was apparent among men starting at CrCl 70 ml/min and among women starting at CrCl 50 ml/min. At any given level of CrCl, men had a larger decrease in hemoglobin than women. For example, compared with subjects with CrCl >80 ml/min, the decrease in hemoglobin for subjects with CrCl 20 to 30 ml/min was 1.0 g/dl in women and 1.4 g/dl in men. A substantial number of subjects with CRI might not have sufficient iron stores to support erythropoiesis as judged by the NKF-K/DOQI transferrin saturation or serum ferritin targets. Among those with CrCl 20 to 30 ml/min, 46% of women and 19% of men had transferrin saturation <20%, and 47% of women and 44% of men had serum ferritin <100 ng/ml. Results estimate that 13.5 million US adults had CrCl 50 ml/min. The overall burden of CRI associated anemia, defined as hemoglobin <11 g/dl, was 800,000 adults. The public health burden of anemia associated with CRI may be substantial, given the large number of people with CRI; and that even a modest reduction in renal function is associated with decreased hemoglobin level.

	Introduction

Top Abstract Introduction Materials and Methods Results Discussion References

 
Burgeoning interest exists in understanding and treating anemia among patients with mild to moderate chronic renal insufficiency (CRI). However, there are few studies of the epidemiology of anemia associated with CRI. Patients with renal insufficiency have reduced hemoglobin levels, mostly as a result of decreased kidney production of erythropoietin (1), but the relation between the degree of renal insufficiency and the magnitude of reduction in hemoglobin is not well defined. To our knowledge, only one previous large-scale study has assessed the relationship between renal function and hemoglobin, particularly including categories of mild renal impairment (2). In that study, which was conducted among patients at a single medical center, subjects had measurements of serum creatinine and hemoglobin performed as part of their clinical care, hence raising the possibility of potential bias (2). For example, those thought to be at higher risk for anemia might be more likely to undergo measurement of hemoglobin. In addition, information on iron status was not presented.

The importance of iron status in the pathophysiology and treatment of anemia among patients with end-stage renal disease has been well described (3). However, little is known about the iron status of patients with less severe reductions in renal function. There have also been few studies of whether iron deficiency interacts with renal insufficiency to exacerbate anemia in patients with mild to moderate CRI.

To address these questions, we took advantage of the nationally representative data available in the Third National Health and Nutrition Examination Survey (NHANES III) (1988 to 1994) (4). Because this is a nationally representative sample, we were able to estimate the likelihood of developing anemia at different levels of renal function in various demographic groups and to estimate the burden of anemia across the spectrum of renal insufficiency among US adults.

	Materials and Methods

Top Abstract Introduction Materials and Methods Results Discussion References

 
NHANES III Population
NHANES III was designed to provide national estimates of the health and nutritional status of the civilian noninstitutionalized population of the United States (4). We downloaded NHANES III data from the following Web site: http://www.cdc.gov/nchs/about/major/nhanes/nh3data.htm#Data Files 1a. In NHANES III, 39,695 people were selected over the course of 6 yr. All NHANES III participants aged >12 yr were eligible for measurement of a complete blood count and a biochemistry profile that included serum creatinine and iron profiles. Examinees reporting hemophilia or recent cancer chemotherapy treatment did not undergo venipuncture. We included in this study only adults aged >18 yr who had measurements of both serum creatinine and hemoglobin.

Assessment of Renal Function
Serum creatinine was measured in NHANES III by the Hitachi 737 automated analyzer (Boehringer Mannheim Diagnostics, Indianapolis, IN) by using a rate Jaffé reaction. Renal function was assessed as the creatinine clearance (CrCl) estimated from the Cockcroft-Gault equation (5):

(1)

The Cockcroft-Gault estimated CrCl has been found to correlate well with measured CrCl in a large variety of patient populations, including both adult men and women (correlation coefficients, 0.8 to 0.9) (6). For the small number of subjects without body weight data (0.2% of the sample), we assigned the gender-specific median values.

Data Management and Statistical Analyses
Data management and statistical analysis were conducted by SAS version 8 (SAS, Cary, NC). NHANES III was a complex stratified random sample of the US population. Appropriate sample weights must therefore be used to obtain national estimates from the sampled population. The sample weights also adjust for noncoverage and nonresponse (7,8).

Hemoglobin and Renal Function
Subjects were divided into eight categories of renal function by their Cockcroft-Gault calculated CrCl as before (2): >80 ml/min (reference), >70 to 80 ml/min, >60 to 70 ml/min, >50 to 60 ml/min, >40 to 50 ml/min, >30 to 40 ml/min, >20 to 30 ml/min, and 20 ml/min. Hemoglobin was examined as the dependent variable in a general linear model (PROC SURVEYREG) with age, race/ethnicity, and categories of CrCl as independent variables.

The value for age was that at the time of the screening interview. Race/ethnicity was defined as non-Hispanic white (reference group), non-Hispanic black, Mexican American, or other. These categories were predefined in NHANES III. The other category included all Hispanics who were not Mexican American and all non-Hispanics from racial groups other than white or black. Gender-specific analyses were performed.

Iron Status among Subjects with CRI
Measures of transferrin saturation and ferritin were available in 15,837 (99%) of 15,971 of the subjects. By use of PROC SURVEYMEANS, we determined the percentage of men and women in the United States in the different categories of CrCl who had transferrin saturation <20% and serum ferritin level <100 ng/ml. These cutoffs were chosen because the National Kidney Foundation (NKF-K/DOQI) Clinical Practice Guidelines recommend maintenance of target transferrin saturation 20% and target serum ferritin level 100 ng/ml to ensure sufficient iron stores to support erythropoiesis among patients with reduced renal function (3).

Interaction between Renal Insufficiency and Iron Deficiency
In addition to transferrin saturation and serum ferritin, erythrocyte protoporphyrin was also available in NHANES III to assess iron status. Iron deficiency is correlated with lower transferrin saturation and serum ferritin but higher erythrocyte protoporphyrin. To ensure that there would be a sufficient number of subjects in each category, we compared subjects in the lowest two gender-specific quartiles of transferrin saturation and serum ferritin with those above the median and those in the top two gender-specific quartiles of erythrocyte protoporphyrin with those below the median (quartile cutoffs given in Table 1). Whether iron deficiency was an effect modifier of the relation between renal insufficiency and hemoglobin was then tested for by entering interaction terms into the linear models.

Burden of Anemia Associated with CRI
To determine the burden of anemia associated with renal insufficiency, we estimated the number of adults in the United States that fell into different demographic and renal function categories by inflating with appropriate weights. The total number of adults with anemia was then calculated by multiplying the corresponding model derived likelihood of having a hemoglobin level <10, <11, or <12 g/dl. The burden of anemia associated with CRI in the United States was defined as the difference between this number and the predicted number of people with anemia if all had CrCl >80 ml/min.

	Results

Top Abstract Introduction Materials and Methods Results Discussion References

 
NHANES III Population
A total of 19,215 NHANES III subjects >18 yr were examined. Older people, Mexican Americans, and African Americans were oversampled in NHANES III. Among the participants, 15,971 (83%) had measurements of both serum creatinine and hemoglobin. Those excluded were on average older (age, mean ± SD, 53 ± 22 yr). The characteristics of the 8506 women and 7465 men studied are shown in Table 1. The mean Cockcroft-Gault estimated CrCl ± SD was 83 ± 33 ml/min for women and 88 ± 32 ml/min for men. The mean hemoglobin level was 13.1 ± 1.2 g/dl for women and 14.9 ± 1.3 g/dl for men.

Hemoglobin and Renal Function
Compared with men with CrCl > 80 ml/min, the hemoglobin in men was significantly lower starting at a CrCl 70 ml/min (Table 2). However, a significant decrease in hemoglobin in women was seen only starting at a CrCl 50 ml/min (Table 2). At every level of CrCl, men had a greater absolute decrease in hemoglobin than women (P < 0.0001). As an example, compared with subjects with a CrCl >80 ml/min, the decrease in hemoglobin for subjects with a CrCl of 20 to 30 ml/min was 1.0 g/dl in women and 1.4 g/dl in men.

In men, there was a suggestion that the effects of iron deficiency and renal insufficiency were more than strictly additive. In a model with categories of renal function and erythrocyte protoporphyrin entered as main terms and their products as interaction terms, we found that men with either CrCl 20 to 30 ml/min or 20 ml/min and also in the highest quartile of erythrocyte protoporphyrin had an additional decrease in hemoglobin of 1.8 g/dl (P = 0.008 and 0.03, respectively). However, this interaction was not observed when transferrin saturation or serum ferritin were used to assess iron status, and it was not observed among women.

Likelihood of Anemia at Different Levels of Renal Function
The likelihood of anemia varied with demographic variables as well as with renal function (Table 4). In multivariate analysis, we noted that a higher likelihood of anemia was found among blacks (versus whites), older (versus younger) men and younger (versus older) women. For example, among non-Hispanic black women aged 61 to 70 yr, the model predicted likelihood of having a hemoglobin <11 g/dl increased from 10% among those with CrCl >80 ml/min to 14% among those with CrCl 40 to 50 ml/min to 32% among those with CrCl 20 to 30 ml/min. The corresponding figures among non-Hispanic white men aged 31 to 40 yr were <1, 1, and 3% (Table 4).

When anemia was defined as hemoglobin <10 g/dl, we estimated that there were 330,000 adult women and 150,000 adult men with anemia associated with CRI. When the cutoff point was raised to hemoglobin <11 g/dl, the estimates were 610,000 women and 230,000 men. When anemia was defined as hemoglobin <12 g/dl, the estimated burden of anemia associated with CRI in the United States among adults was 1,200,000 women and 390,000 men.

	Discussion

Top Abstract Introduction Materials and Methods Results Discussion References

 
Increasing attention is being paid to understanding and treating anemia among patients with CRI not yet requiring dialysis. In this population, anemia contributes to adverse health effects such as left ventricular hypertrophy (9–11). Anemia treatment with epoetin might ameliorate ventricular hypertrophy and improve quality of life and other measures of health (12–16). The National Kidney Foundation (NKF-K/DOQI) Clinical Practice Guidelines recommend an evaluation of anemia among patients with renal insufficiency when the hemoglobin is <11 g/dl among premenopausal women and <12 g/dl among adult men and postmenopausal women (3). Epoetin treatment is recommended for patients with CRI, whether dialysis dependent or not, to achieve a target hemoglobin of 11 to 12 g/dl (3). Similar guidelines have been put forth by the European Renal Association/European Dialysis and Transplantation Association (17).

Much remains unknown about anemia in patients with mild to moderate CRI. We have shown from a study at a single institution that a decrease in hemoglobin could be detected at more modest degrees of renal insufficiency than previously realized (2). In addition, at any given level of CrCl, men had a larger decrease in hemoglobin than women (2). We now confirm and extend these findings in a nationally representative sample. Unlike in our previous study of ambulatory patients in whom the indications for measuring serum creatinine and hemoglobin were unknown, the analysis presented here is based on measurements routinely performed as part of NHANES III. The similar quantitative relations between hemoglobin and CrCl observed in two independent cohorts provide strong evidence that these are unbiased findings. The magnitude of the decrease in hemoglobin observed among those with mild to moderate CRI is important because prospective studies have shown that in this range of hemoglobin, each 0.5 g/dl decrease is associated with an odds ratio for increase in left ventricular mass of 1.3 (11).

Although extensive literature exists on the importance of iron status in determining response to administered epoetin among patients with end-stage renal disease, few studies have examined iron status or the relationship between iron status and hemoglobin among patients with reduced endogenous erythropoietin production. The observation that patients with end-stage renal disease appear to have a "functional iron deficiency" (3) led us to hypothesize that not only were iron deficiency and renal insufficiency both independent risk factors for anemia, but there might be an interaction. The same degree of iron deficiency might be associated with a greater drop in hemoglobin in patients with reduced renal function than in patients with preserved renal function.

Because no single biochemical indicator is consistently diagnostic of iron deficiency (18,19), we studied serum ferritin, a measure of storage iron (20); transferrin saturation, a measure of current iron supply to tissues (20); and erythrocyte protoporphyrin, an indicator of iron supply to erythroid precursors over a longer term (20). We found that a large fraction of US patients with CRI not yet requiring dialysis had iron stores below the NKF-K/DOQI targets (although there was no consistent relationship between measures of iron status and CrCl).

The effects of iron deficiency and renal insufficiency appeared more than strictly additive among men only when erythrocyte protoporphyrin was used as a measure of iron status. Further studies are therefore needed to clarify whether there is indeed an interaction between iron deficiency and renal insufficiency and whether this differs by gender.

Our estimate of the prevalence of renal insufficiency in the United States is similar to that of other investigators. Both also using NHANES III data, Jones et al. (21) estimated that 6.2 million Americans aged 12 yr had serum creatinine 1.5 mg/dl, and Wei et al. (22) estimated that 12.5 million aged 17 yr had CrCl <50 ml/min per 1.73 m². In agreement with previous research, we observed that blacks, older men, and younger women have, on average, lower hemoglobin levels (23,24). Given the large number of subjects with reduced renal function, and given the fact that increased risk of anemia is seen even among patients with only modest reductions in CrCl, the burden of anemia associated with CRI is substantial.

Our estimate of the number of people in the United States with anemia associated with CRI is higher than that found by Strauss et al. (25), who concluded that between 68,000 and 75,000 people had "predialysis" renal insufficiency and anemia (defined as hematocrit <30%). Possible reasons for the difference in prevalence estimates include the fact that Strauss et al. (25) used data from NHANES II, which was conducted from 1976 to 1980; their population estimate was based on only 44 sampled people with serum creatinine between 2.0 and 8.0 mg/dl, and the estimate of proportion of patients with hematocrit <30% was based on pooling 182 patients from three different studies.

The advantages of our modeling approach over direct assessment of the percentage of people falling below hemoglobin cutoffs include full use of the information available in the continuously distributed outcome (hemoglobin) and smoothing out of sample variation that was evident because of the small sample sizes for some of the demographic and renal function categories. For example, there might not be a 61 to 70 yr-old non-Hispanic white woman with CrCl 20 to 30 ml/min sampled in NHANES III (and therefore no directly observed hemoglobin level), although such people exist in the United States.

The findings from the report presented here should be interpreted in the context of the study design. Only calculated CrCl were used; actual measurements of CrCl or GFR were not done. As this was a cross-sectional study, we did not have information on how hemoglobin changes over time in people with progressive renal insufficiency. Although NHANES III oversampled some subjects at higher risk for renal insufficiency (e.g., elderly subjects and minorities), sampling gaps remained in some demographic and renal function subgroups. For example, the number of NHANES III subjects with CrCl 30 ml/min was relatively small, and this decreased our modeling precision. We probably underestimated the number of subjects with anemia associated with CRI because we excluded people in NHANES III who were examined but who did not have measures of creatinine or hemoglobin, and these examinees on average were older.

In conclusion, by using the nationally representative NHANES III data, we found that a decrease in the hemoglobin level was apparent even among adults with only modest decrements in renal function. The magnitude of the decrease in hemoglobin was greater for men than for women at any level of CrCl. Clearly, the overall burden of anemia associated with CRI in the United States is substantial. Future studies should examine the benefits and cost-effectiveness of treating anemia in subjects with mild to moderate CRI.

	Acknowledgments

 
C-YH was supported by the American Kidney Fund Clinical Scientist in Nephrology Award. GCC was supported by the National Institutes of Health (RO1 DK 52866).

	References

Top Abstract Introduction Materials and Methods Results Discussion References

 

1. Remuzzi G, Minetti L: Hematologic consequences of renal failure.In: Brenner and Rector’s The Kidney, Vol. 2, 6th Ed., edited by Brenner BM, Philadelphia: WB Saunders, 2000,pp 2079– 2102
2. Hsu CY, Bates DW, Kuperman GJ, Curhan GC: Relationship between hematocrit and renal function in men and women. Kidney Int 59: 725–731, 2001[CrossRef][Medline]
3. National Kidney Foundation NKF-K/DOQI clinical practice guidelines for anemia of chronic kidney disease: Update 2000. Am J Kidney Dis 2001; 37 [Suppl 1]: S182–S238[Medline]
4. National Center for Health Statistics. Third National Health and Nutrition Examination Survey, 1988–1994: Plan and Operation of the Third National Health and Nutrition Examination Survey, 1988–94 [CD-ROM], revised September 1997. Hyattsville, MD, Centers for Disease Control and Prevention, 1996
5. Cockcroft DW, Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron 16: 31–41, 1976[Medline]
6. %Gault MH, Longerich LL, Harnett JD, Wesolowski C: Predicting glomerular function from adjusted serum creatinine. Nephron 62: 249–256, 1992[Medline]
7. National Center for Health Statistics. Third National Health and Nutrition Examination Survey, 1988–1994: Weighting and Estimation Methodology [CD-ROM], revised September 1997. Hyattsville, MD, Centers for Disease Control and Prevention, 1996
8. National Center for Health Statistics. Third National Health and Nutrition Examination Survey, 1988–1994: Analytic and Reporting Guidelines [CD-ROM], revised September 1997. Hyattsville, MD, Centers for Disease Control and Prevention, 1996
9. Levin A, Singer J, Thompson CR, Ross H, Lewis M: Prevalent left ventricular hypertrophy in the predialysis population: Identifying opportunities for intervention. Am J Kidney Dis 27: 347–354, 1996[Medline]
10. Tucker B, Fabbian F, Giles M, Thuraisingham RC, Raine AE, Baker LR: Left ventricular hypertrophy and ambulatory blood pressure monitoring in chronic renal failure. Nephrol Dial Transplant 12: 724–728, 1997[Abstract/Free Full Text]
11. Levin A, Thompson CR, Ethier J, Carlisle EJ, Tobe S, Mendelssohn D, Burgess E, Jindal K, Barrett B, Singer J, Djurdjev O: Left ventricular mass index increase in early renal disease: Impact of decline in hemoglobin. Am J Kidney Dis 34: 125–134, 1999[Medline]
12. US Recombinant Human Erythropoietin Predialysis Study Group. Double-blind, placebo-controlled study of the therapeutic use of recombinant human erythropoietin for anemia associated with chronic renal failure in predialysis patients. Am J Kidney Dis 18: 50–59, 1991[erratum Am J Kidney Dis 18: 420, 1991][Medline]
13. Roth D, Smith RD, Schulman G, Steinman TI, Hatch FE, Rudnick MR, Sloand JA, Freedman BI, Williams WW Jr, Shadur CA, Benz RL, Teehan BP, Revicki DA, Sarokhan BJ, Abels RI: Effects of recombinant human erythropoietin on renal function in chronic renal failure predialysis patients. Am J Kidney Dis 24: 777–784, 1994[Medline]
14. Revicki DA, Brown RE, Feeny DH, Henry D, Teehan BP, Rudnick MR, Benz RL: Health-related quality of life associated with recombinant human erythropoietin therapy for predialysis chronic renal disease patients. Am J Kidney Dis 25: 548–554, 1995[Medline]
15. Portolés J, Torralbo A, Martin P, Rodrigo J, Herrero JA, Barrientos A: Cardiovascular effects of recombinant human erythropoietin in predialysis patients. Am J Kidney Dis 29: 541–548, 1997[Medline]
16. Hayashi T, Suzuki A, Shoji T, Togawa M, Okada N, Tsubakihara Y, Imai E, Hori M: Cardiovascular effect of normalizing the hematocrit level during erythropoietin therapy in predialysis patients with chronic renal failure. Am J Kidney Dis 35: 250–256, 2000[Medline]
17. European best practice guidelines for the management of anemia in patients with chronic renal failure. Nephrol Dial Transplant 14 [Suppl 5]: 5–13, 1999[Free Full Text]
18. Expert Scientific Working Group: Summary of a report on assessment of the iron nutritional status of the United States population. Am J Clin Nutr 42: 1318–1330, 1985[Abstract/Free Full Text]
19. Cook JD, Finch CA, Smith NJ: Evaluation of the iron status of a population. Blood 48: 449–455, 1976[Abstract/Free Full Text]
20. Brittenham GM: Disorders of iron metabolism: Iron deficiency and overload.In: Hematology: Basic Principles and Practice, 3rd Ed., edited by Hoffman R, Benz EJ, Shattil SJ, Furie B, Cohen HJ, Silberstein LE, et al. New York, Churchill Livingstone, 2000,pp 397–428
21. Jones CA, McQuillan GM, Kusek JW, Eberhardt MS, Herman WH, Coresh J, Salive M, Jones CP, Agodoa LY: Serum creatinine levels in the US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 32: 992–999, 1998[erratum Am J Kidney Dis 35: 178, 2000][Medline]
22. Wei GL, Coresh J, Jones CA, McQuillan G, Brancati FL, Klag MJ: High blood pressure and the burden of renal insufficiency in the United States: NHANES III, 1988–1994 [Abstract]. J Am Soc Nephrol 9: 162A, 1998
23. Dallman PR, Yip R, Johnson C: Prevalence and causes of anemia in the United States, 1976 to 1980. Am J Clin Nutr 39: 437–445, 1984[Abstract/Free Full Text]
24. Garn SM, Smith NJ, Clark DC: The magnitude and the implications of apparent race differences in hemoglobin values. Am J Clin Nutr 28: 563–566, 1975[Free Full Text]
25. Strauss MJ, Port FK, Somen C, Wolfe RA: An estimate of the size of the US predialysis population with renal insufficiency and anemia. Am J Kidney Dis 21: 264–269, 1993[Medline]

This article has been cited by other articles:

				M. Kobayashi, N. Hirawa, K. Yatsu, Y. Kobayashi, Y. Yamamoto, S. Saka, D. Andoh, Y. Toya, G. Yasuda, and S. Umemura Relationship between silent brain infarction and chronic kidney disease Nephrol. Dial. Transplant., August 12, 2008; (2008) gfn419v1. [Abstract] [Full Text] [PDF]

				S. Tomasello Anemia of Chronic Kidney Disease Journal of Pharmacy Practice, June 1, 2008; 21(3): 181 - 195. [Abstract] [PDF]

				B. S. Spinowitz Anemia management in patients on peritoneal dialysis: efficacy and safety of epoetin {delta} Haematologica, May 1, 2008; 93(5): 761 - 764. [Abstract] [Full Text] [PDF]

				I. C. Macdougall, R. Walker, R. Provenzano, F. de Alvaro, H. R. Locay, P. C. Nader, F. Locatelli, F. C. Dougherty, U. Beyer, and on behalf of the ARCTOS study investigators C.E.R.A. Corrects Anemia in Patients with Chronic Kidney Disease not on Dialysis: Results of a Randomized Clinical Trial Clin. J. Am. Soc. Nephrol., March 1, 2008; 3(2): 337 - 347. [Abstract] [Full Text] [PDF]

				N.M.P. Annear, D. Banerjee, J. Joseph, T.H. Harries, S. Rahman, and J.B. Eastwood Prevalence of chronic kidney disease stages 3-5 among acute medical admissions: another opportunity for screening QJM, February 1, 2008; 101(2): 91 - 97. [Abstract] [Full Text] [PDF]

				L. G. Glynn, D. Reddan, J. Newell, J. Hinde, B. Buckley, and A. W. Murphy Chronic kidney disease and mortality and morbidity among patients with established cardiovascular disease: a West of Ireland community-based cohort study Nephrol. Dial. Transplant., September 1, 2007; 22(9): 2586 - 2594. [Abstract] [Full Text] [PDF]

				W. H. Horl, Y. Vanrenterghem, P. Aljama, P. Brunet, R. Brunkhorst, L. Gesualdo, I. Macdougall, C. Wanner, and B. Wikstrom OPTA: Optimal treatment of anaemia in patients with chronic kidney disease (CKD) Nephrol. Dial. Transplant., June 1, 2007; 22(suppl_3): iii20 - iii26. [Full Text] [PDF]

				K. E. Ensrud, L.-Y. Lui, B. C. Taylor, A. Ishani, M. G. Shlipak, K. L. Stone, J. A. Cauley, S. A. Jamal, D. M. Antoniucci, S. R. Cummings, et al. Renal Function and Risk of Hip and Vertebral Fractures in Older Women Arch Intern Med, January 22, 2007; 167(2): 133 - 139. [Abstract] [Full Text] [PDF]

				W. F. Keane, Z. Zhang, P. A. Lyle, M. E. Cooper, D. de Zeeuw, J.-P. Grunfeld, J. P. Lash, J. B. McGill, W. E. Mitch, G. Remuzzi, et al. Risk Scores for Predicting Outcomes in Patients with Type 2 Diabetes and Nephropathy: The RENAAL Study Clin. J. Am. Soc. Nephrol., July 1, 2006; 1(4): 761 - 767. [Abstract] [Full Text] [PDF]

				B. R. Hemmelgarn, D. A. Southern, K. H. Humphries, B. F. Culleton, M. L. Knudtson, W. A. Ghali, and for the Alberta Provincial Project for Outcomes As Refined characterization of the association between kidney function and mortality in patients undergoing cardiac catheterization Eur. Heart J., May 2, 2006; 27(10): 1191 - 1197. [Abstract] [Full Text] [PDF]

				M. Shlipak and C. Stehman-Breen Observational Research Databases in Renal Disease J. Am. Soc. Nephrol., December 1, 2005; 16(12): 3477 - 3484. [Abstract] [Full Text] [PDF]

				A. Ble, J. C. Fink, R. C. Woodman, M. A. Klausner, B. G. Windham, J. M. Guralnik, and L. Ferrucci Renal Function, Erythropoietin, and Anemia of Older Persons: The InCHIANTI Study Arch Intern Med, October 24, 2005; 165(19): 2222 - 2227. [Abstract] [Full Text] [PDF]

				M. Germain, C. V. Ram, S. Bhaduri, K. L. Tang, M. Klausner, and M. Curzi Extended epoetin alfa dosing in chronic kidney disease patients: a retrospective review Nephrol. Dial. Transplant., October 1, 2005; 20(10): 2146 - 2152. [Abstract] [Full Text] [PDF]

				M. Kurella, G. M. Chertow, L. F. Fried, S. R. Cummings, T. Harris, E. Simonsick, S. Satterfield, H. Ayonayon, and K. Yaffe Chronic Kidney Disease and Cognitive Impairment in the Elderly: The Health, Aging, and Body Composition Study J. Am. Soc. Nephrol., July 1, 2005; 16(7): 2127 - 2133. [Abstract] [Full Text] [PDF]

				M. J. Sarnak, R. Katz, C. O. Stehman-Breen, L. F. Fried, N. S. Jenny, B. M. Psaty, A. B. Newman, D. Siscovick, M. G. Shlipak, and and the Cardiovascular Health Study* Cystatin C Concentration as a Risk Factor for Heart Failure in Older Adults Ann Intern Med, April 5, 2005; 142(7): 497 - 505. [Abstract] [Full Text] [PDF]

				D. J. Leehey, D. J. Palubiak, S. Chebrolu, and R. Agarwal Sodium ferric gluconate causes oxidative stress but not acute renal injury in patients with chronic kidney disease: a pilot study Nephrol. Dial. Transplant., January 1, 2005; 20(1): 135 - 140. [Abstract] [Full Text] [PDF]

				G. F.M. Strippoli, J. C. Craig, C. Manno, and F. P. Schena Hemoglobin Targets for the Anemia of Chronic Kidney Disease: A Meta-analysis of Randomized, Controlled Trials J. Am. Soc. Nephrol., December 1, 2004; 15(12): 3154 - 3165. [Abstract] [Full Text] [PDF]

				A. S. Go, G. M. Chertow, D. Fan, C. E. McCulloch, and C.-y. Hsu Chronic Kidney Disease and the Risks of Death, Cardiovascular Events, and Hospitalization N. Engl. J. Med., September 23, 2004; 351(13): 1296 - 1305. [Abstract] [Full Text] [PDF]

				M. C. Thomas, R. J. MacIsaac, C. Tsalamandris, L. Molyneaux, I. Goubina, G. Fulcher, D. Yue, and G. Jerums Anemia in Patients with Type 1 Diabetes J. Clin. Endocrinol. Metab., September 1, 2004; 89(9): 4359 - 4363. [Abstract] [Full Text] [PDF]

				M. C. Thomas, R. J. MacIsaac, C. Tsalamandris, L. Molyneaux, I. Goubina, G. Fulcher, D. Yue, and G. Jerums The burden of anaemia in type 2 diabetes and the role of nephropathy: a cross-sectional audit Nephrol. Dial. Transplant., July 1, 2004; 19(7): 1792 - 1797. [Abstract] [Full Text] [PDF]

				L. P. McMahon, S. D. Roger, and A. Levin Development, Prevention, and Potential Reversal of Left Ventricular Hypertrophy in Chronic Kidney Disease J. Am. Soc. Nephrol., June 1, 2004; 15(6): 1640 - 1647. [Abstract] [Full Text] [PDF]

				D. R. Thomas Anemia and Quality of Life: Unrecognized and Undertreated J. Gerontol. A Biol. Sci. Med. Sci., March 1, 2004; 59(3): M238 - M241. [Full Text] [PDF]

				S. D. Roger, L. P. McMahon, A. Clarkson, A. Disney, D. Harris, C. Hawley, H. Healy, P. Kerr, K. Lynn, A. Parnham, et al. Effects of Early and Late Intervention with Epoetin {alpha} on Left Ventricular Mass among Patients with Chronic Kidney Disease (Stage 3 or 4): Results of a Randomized Clinical Trial J. Am. Soc. Nephrol., January 1, 2004; 15(1): 148 - 156. [Abstract] [Full Text] [PDF]

				C. T. Jurkovitz, J. L. Abramson, L. V. Vaccarino, W. S. Weintraub, and W. M. McClellan Association of High Serum Creatinine and Anemia Increases the Risk of Coronary Events: Results from the Prospective Community-Based Atherosclerosis Risk in Communities (ARIC) Study J. Am. Soc. Nephrol., November 1, 2003; 14(11): 2919 - 2925. [Abstract] [Full Text] [PDF]

				M. C. Thomas, R. J. MacIsaac, C. Tsalamandris, D. Power, and G. Jerums Unrecognized Anemia in Patients With Diabetes: A cross-sectional survey Diabetes Care, April 1, 2003; 26(4): 1164 - 1169. [Abstract] [Full Text] [PDF]

				C.-y. Hsu and G. C. Curhan Anaemia among subjects with chronic renal insufficiency Nephrol. Dial. Transplant., March 1, 2003; 18(3): 623 - 623. [Full Text] [PDF]

				C.-y. Hsu, C. E. McCulloch, and G. C. Curhan Iron Status and Hemoglobin Level in Chronic Renal Insufficiency J. Am. Soc. Nephrol., November 1, 2002; 13(11): 2783 - 2786. [Abstract] [Full Text] [PDF]

				C.-y. Hsu and G. M. Chertow Elevations of serum phosphorus and potassium in mild to moderate chronic renal insufficiency Nephrol. Dial. Transplant., August 1, 2002; 17(8): 1419 - 1425. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hsu, C.-y. Articles by Curhan, G. C. Search for Related Content PubMed PubMed Citation Articles by Hsu, C.-y. Articles by Curhan, G. C.